NCT04123769已完成1 期
Pharmacokinetics of Hydronidone Capsules in Patients With Chronic Hepatitis B Complicated With Liver Fibrosis and Mild Hepatic Insufficiency
Beijing Continent Pharmaceutical Co, Ltd.1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2019年9月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
- Evaluate the pharmacokinetic (PK) characteristics of Hydronidone capsule in target patients (patients with chronic viral hepatitis b with liver fibrosis) and special population (patients with mild liver dysfunction).
- To evaluate the effect of oral Hydronidone capsule on QT/QTc in patients with chronic viral hepatitis b accompanied by hepatic fibrosis and mild hepatic dysfunction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18-65 years (including 18 and 65 years);
- •BMI 18-26 (including 18 and 26) [BMI= weight (kg)/height 2 (m2)];
- •History of chronic hepatitis b, HBsAg positive ≥6 months;
- •ALT < 5 times ULN (standard upper limit);
- •TBiL < 2 times ULN (standard upper limit);
- •ALP < 1.5 times ULN (standard upper limit);
- •Liver elastic hardness test confirmed significant liver fibrosis (LSM≥ 7.3kpa);
- •Scores assessed by child-pugh system are 5 or 6;
- •Patients currently receiving antiviral treatment with entecavir;
- •The subject (or his/her partner) has no pregnancy plan during and within 6 months after the trial and voluntarily takes effective physical contraception and has no sperm or egg donation plan;
- •Before the trial, I have had a detailed understanding of the nature, significance, possible benefits, possible inconveniences and potential risks of the trial, and I have volunteered to participate in the clinical trial. I am able to communicate well with the investigator, comply with the requirements of the whole study, and have signed a written informed consent.
排除标准
- •Those who do not meet any of the inclusion criteria;
- •(consultation) participants in clinical trials of other drugs in recent 3 months;
- •(consultation) any drugs that inhibit or induce drug metabolism in the liver (common liver enzyme inducers: barbiturates (phenobarbital is the most common), carbamazepine, aminoximate, griseofulvin, aminopropyl ester, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide);
- •(consultation) select those who drank excessive amounts of tea, coffee or caffeinated beverages (more than 8 cups a day, 1 cup =250mL) every day during the first three months; Or from the screening to -1 days after admission, intake of any food or drink containing caffeine and xanthine (such as coffee, strong tea, chocolate, etc.) and other special diet that affects the absorption, distribution, metabolism and excretion of drugs;
- •(consultation) patients who had taken food or drinks containing enzymes that can induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice, orange juice and other compounds rich in flavonoids or citrus glycosides) before admission were screened.
- •(consultation) screening: drinking more than 14 standard units of alcohol per week in the first 3 months (1 standard unit contains 14g of alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or cannot abstain from alcohol during the test period; Or taking any alcohol products within 24 hours before the first dose of the study;
- •(consultation) select those who smoke more than 5 cigarettes per day within the first 3 months, or cannot stop using any tobacco products during the trial; Screening for smoking or using any tobacco products up to admission;
- •(consultation) previous history of drug abuse and drug abuse;
- •(consultation) patients with upper gastrointestinal massive bleeding or active peptic ulcer within the first 3 months were enrolled;
- •(consultation) patients with serious diseases of cardiovascular, pulmonary, renal, endocrine, nervous and blood systems and mental disorders;
- •(consultation) allergy: if allergic to two or more drugs or food; Lactose intolerant;
- •AFP > 100 μg /L;
- •B ultrasound showed obvious space-occupying lesions in the liver, suggesting tumor;
- •Patients with decompensated liver cirrhosis;
- •Patients with malignant tumors;
- •Received non-entecavir nucleoside analogues or interferon antiviral therapy within 3 months before inclusion;
- •Pregnant and/or lactating women;
- •Subjects who are legally disabled according to the law of the People's Republic of China on the protection of disabled persons (April 2008);
- •Alcohol breath test results greater than 0.0mg/100mL;
- •Positive urine drug screening;
- •Patients with suspected poor compliance;
- •The investigator considers that there are any circumstances that may affect the subject's informed consent or adherence to the study protocol, or participation in the study may affect the results of the study or their own safety.
研究组 & 干预措施
Drug group
Experimental
干预措施: Hydronidone (Drug)
结局指标
主要结局
Cmax
时间窗: up to 24 weeks
Tmax
时间窗: up to 24 weeks
AUC
时间窗: up to 24 weeks
QT/QTc
时间窗: up to 24 weeks
次要结局
- CL/F(up to 24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study on Pharmacokinetics of HydronidonePharmacokinetics of HydronidoneNCT04162821Beijing Continent Pharmaceutical Co, Ltd.48
已完成
不适用
Study on Hydronidone Capsule BEHealthyNCT04125056Beijing Continent Pharmaceutical Co, Ltd.40
已完成
1 期
Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese SubjectsHydronidoneNCT04124081Beijing Continent Pharmaceutical Co, Ltd.12
已完成
4 期
Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study)Septic ShockPeritonitisNCT02805049Centre Hospitalier Universitaire de Nīmes24
进行中（未招募）
1 期
Pharmacokinetic study on echinocandins for patients with septic shock following secondary peritonitisEUCTR2016-002708-17-FRCHU de NIMES24